Infertility, IVF
Conditions
Brief summary
Follitropin delta (Rekovelle) algorithm established by Ferring provides personalized gonadotrophin doses based on each patient's weight and AMH. As a result, risks of stimulation failure or ovarian hyperstimulation syndrome (OHSS) during an in vitro fertilization (IVF) cycle are minimized. As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.
Detailed description
The purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of Rekovelle and Menopur duting an antagonist IVF cycle. Based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.
Interventions
OTHERStudy chart review
Evaluation of the IVF cycle using the prescribed medication
Sponsors
Clinique Ovo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
* Women of 18 years of age or older having provided consent to chart access for scientific publication in the IVF consent form * Antagonist IVF cycle using combination of Rekovelle and Menopur for stimulation according to the modified protocol employed at clinique ovo without deviation * Presence of both ovaries
Exclusion criteria
* Second cycle of Duo-Stim IVF
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify the population where a simplified IVF monitoring is conceivable | Up to 3 weeks | Rate of Rekovelle and / or Menopur dose modification before day 10 ultrasound |
Countries
Canada
Outcome results
None listed